Beyond Air

Israel - RehovotBiotechnology1 H-1B visas (FY2023)

Focus: Beyond Air is an Israeli biotechnology company specializing in nitric oxide (NO) therapy for respiratory and infectious diseases. The company is developing the LungFit delivery system to enable inhaled NO treatment across multiple indications.

Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Beyond Air

AI assessmentNot Hiring

No open roles listed right now. Follow Beyond Air to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LungFit™

Viral Pneumonia

N/A

Clinical Trials (1)

NCT04606407Inhaled NO for the Treatment of Viral Pneumonia in Adults

N/A

Help build intelligence for Beyond Air

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering a novel modality (nitric oxide therapy) with broad applicability across respiratory, infectious, and oncology indications—rare opportunity to shape emerging science
Diversified pipeline of 10 trials spanning Phase 1 through Phase 3, with bronchiolitis Phase 3 program potentially near inflection point
Israeli biotech hub location offers access to robust innovation ecosystem and potential regulatory pathways

Watch Out For

Pre-revenue stage with no disclosed funding, cash position, or employee count—significant execution and capital raise risk
Only 1 active job opening and minimal hiring activity (Sales only) suggest very early stage or resource constraints
Sparse clinical publication record (0 publications) and limited public visibility on trial progress or mechanisms of action

Generated by Claude from Beyond Air's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Nitric Oxide delivered via LungFit™ system

Corona Virus Infection

N/A

Clinical Trials (1)

NCT04397692Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

N/A

LungFit

Non-Tuberculous Mycobacterial Pneumonia

N/A

Clinical Trials (1)

NCT04685720A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients

N/A